EyePoint (EYPT) Stock Price, Financials & Analysis

Key Stats

Market Cap31.41 Mn

P/E-0.10

FCF (Yr)-243.39 Mn

ROA (Yr)-59.29

EV to EBIT2.78

Net Income (Yr)-231.96 Mn

Enterprise Value-881.72 Mn

Add ratio to table…

About

EyePoint, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases. The company uses its proprietary bioerodible Durasert E technology to enable sustained intraocular drug delivery. Its lead product candidate DURAVYU combines the small molecule inhibitor vorolanib with the Durasert E platform to target vascular endothelial growth factor mediated retinal diseases. DURAVYU is being evaluated in phase three trials for wet age related macular degeneration and diabetic macular edema. Additional preclinical programs evaluate razoprotafib formulated in Durasert E. The company is headquartered in Watertown Massachusetts and operates a commercial manufacturing facility in Northbridge Massachusetts. Its technology has been used in four FDA approved products that utilize a non erodible formulation of the Durasert platform.

EyePoint generates revenue primarily from licensing its drug delivery technology and product candidates to partners. The company receives upfront payments milestone payments and royalties on net sales from licensed products. For example it has licensed YUTIQ to ANI for an upfront payment of $75 million and is entitled to additional royalties. It also has agreements with Equinox and Betta concerning vorolanib. Additionally the company manufactures and supplies certain products to partners generating further revenue.

EyePoint occupies a niche in the ophthalmology market as a developer of sustained delivery therapies for retinal diseases. It faces competition from established anti VEGF agents such as Lucentis Eylea Vabysmo and Beovu as well as their biosimilars. These competitors require frequent intravitreal injections while EyePoint aims to offer less frequent dosing through its durable implant. The company's differentiated approach combines VEGF inhibition with anti inflammatory activity via vorolanib which may provide advantage over single mechanism therapies. Additionally its proprietary Durasert technology already has FDA approved products demonstrating a proven track record in drug delivery.

The company serves patients suffering from retinal conditions such as wet age related macular degeneration and diabetic macular edema. Physicians who administer intravitreal injections are the direct customers for its therapeutic products. EyePoint also works with pharmaceutical partners including ANI Ocumension Equinox and Betta which license its technology or co develop product candidates.

How EyePoint ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.10xMedian 17.8x 5^th
P/FCFNegative free cash flow −0.11xMedian 21.0x 5^th
P/Operating cash flowNegative operating cash flow −0.11xMedian 16.8x 5^th
P/S 11.0xMedian 8.14x 44^th
P/B 0.18xMedian 2.02x 94^th
P/Tangible book 0.18xMedian 2.24x 95^th
EV/EBITDANet cash exceeds market value 0.48xMedian 15.7x Not meaningful —
EV/EBITNet cash exceeds market value 0.47xMedian 20.9x Not meaningful —
EV/RevenueNet cash exceeds market value −53.7xMedian 5.92x Not meaningful —
EV/FCFNet cash exceeds market value 0.55xMedian 22.0x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 0.56xMedian 18.3x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.01Median 0.36 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −94.6%Median 11.0% 4^th
Revenue CAGR (3Y) −57.9%Median 10.4% 6^th
Gross profit growth (1Y) −97.6%Median 11.8% 4^th
Gross profit CAGR (3Y) −66.2%Median 12.3% 3^rd
Operating income growth (1Y) −67.7%Median −1.6% 18^th
Operating income CAGR (3Y) −43.9%Median 1.4% 12^th
Net income growth (1Y) −74.8%Median −3.3% 21^st
Net income CAGR (3Y) −42.5%Median −0.1% 13^th
EPS growth (1Y) −41.3%Median 22.4% 22^nd
EPS CAGR (3Y) −7.9%Median 25.9% 23^rd
Operating cash flow growth (1Y) −40.3%Median −0.4% 24^th
Operating cash flow CAGR (3Y) −174%Median 2.1% 1^st
Free cash flow growth (1Y) −39.8%Median −0.1% 24^th
Free cash flow CAGR (3Y) −192%Median 2.5% 1^st

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 41.8%Median 74.2% 21^st
EBITDA margin <−10,000%Median −214% 5^th
Operating margin <−10,000%Median −213% 6^th
Pretax margin <−10,000%Median −205% 7^th
Net margin <−10,000%Median −196% 6^th
FCF margin −9,727%Median −181% 6^th
Operating cash flow margin −9,584%Median −175% 6^th
Return on equity −156%Median −54.7% 18^th
Return on assets −120%Median −41.1% 18^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −147%Median −47.8% 16^th
Asset turnover 0.01xMedian 0.18x 12^th
Cash conversion (OCF / net income)Net income is not positive 0.87xMedian 1.14x Not meaningful —
Stock comp / revenue 1,263%Median 29.2% 7^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.27x No data —
Net debt / EBITDA —Median 1.22x No data —
Debt / FCF —Median 3.65x No data —
Liabilities / assets 27.1%Median 32.3% 57^th
Equity / assets 72.9%Median 67.7% 57^th
Interest coverage —Median −10.0x No data —
Current ratio 4.50xMedian 4.37x 51^st
Quick ratio 4.30xMedian 3.65x 53^rd
Cash ratio 4.30xMedian 3.35x 55^th
Altman Z-score −11.4Median −0.80 21^st

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.5% No dividend —
Net buyback yieldAbove 100% of market value −641%Median −3.5% Not meaningful —
Shareholder yieldAbove 100% of market value −641%Median −2.4% Not meaningful —
Payout ratio (earnings) —Median 79.0% No dividend —
Payout ratio (FCF) —Median 61.8% No dividend —
Dividend growth (1Y) —Median 2.9% No dividend —
Dividend CAGR (3Y) —Median 3.3% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,261.99 Bn	45.76	14.60	49.50 Bn
2	JNJ	Johnson & Johnson	678.93 Bn	42.18	6.83	44.65 Bn
3	ABBV	AbbVie Inc.	518.29 Bn	50.12	7.85	80.90 Bn
4	MRK	Merck & Co., Inc.	365.98 Bn	149.20	5.43	53.78 Bn
5	NVS	Novartis Ag	316.85 Bn	17.91	5.08	-
6	AZN	Astrazeneca Plc	293.40 Bn	26.60	4.94	-11.96 Bn
7	AMGN	Amgen Inc	251.78 Bn	26.81	6.47	54.01 Bn
8	EYPT	EyePoint, Inc.	0.03 Bn	-0.10	11.26	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,261.99 Bn

45.76

14.60

49.50 Bn

JNJ

Johnson & Johnson

678.93 Bn

42.18

6.83

44.65 Bn

ABBV

AbbVie Inc.

518.29 Bn

50.12

7.85

80.90 Bn

MRK

Merck & Co., Inc.

365.98 Bn

149.20

5.43

53.78 Bn

NVS

Novartis Ag

316.85 Bn

17.91

5.08

AZN

Astrazeneca Plc

293.40 Bn

26.60

4.94

-11.96 Bn

AMGN

Amgen Inc

251.78 Bn

26.81

6.47

54.01 Bn

EYPT

EyePoint, Inc.

0.03 Bn

-0.10

11.26

EyePoint EYPT

About

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

How EyePoint ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

EyePoint EYPT

About

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

How EyePoint ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password